Trial intelligence / Profile preview

AQUA07 alone and with lorlatinib in ALK-positive non-small cell lung cancer

jRCT2031260134Phase 1Recruiting

Sponsor

Chugai Pharmaceutical Co., Ltd.

Start

Jul 2026

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

2